Literature DB >> 3487285

Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats.

R G D'Antonio, D B Johnson, R E Winn, A F van Dellen, M E Evans.   

Abstract

Daily administration of 1 mg of folinic acid to immunosuppressed rats with incipient or established Pneumocystis carinii pneumonia did not impair the capacity of trimethoprim-sulfamethoxazole to either prevent or treat this disease. These observations constitute the first experimental support for the use of folinic acid to prevent or control cytopenias that occur in patients with Pneumocystis carinii pneumonia who are under trimethoprim-sulfamethoxazole treatment.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3487285      PMCID： PMC176401          DOI： 10.1128/AAC.29.2.327

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  THE TREATMENT OF TOXOPLASMA UVEITIS.

Authors:  C L GILES
Journal:  Am J Ophthalmol       Date:  1964-10       Impact factor: 5.258

2.  Effects of trimethoprim on folate metabolism in man.

Authors:  S B Kahn; S A Fein; I Brodsky
Journal:  Clin Pharmacol Ther       Date:  1968 Sep-Oct       Impact factor: 6.875

3.  Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia.

Authors:  W T Hughes; B L Smith
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

4.  Acute megaloblastic anemia induced by high-dose trimethoprim-sulfamethoxazole.

Authors:  N L Kobrinsky; N K Ramsay
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

5.  Trimethoprim and sulphamethoxazole inhibition of haematopoiesis in vitro.

Authors:  D W Golde; N Bersch; S G Quan
Journal:  Br J Haematol       Date:  1978-11       Impact factor: 6.998

6.  Leucopenia associated with trimethoprim-sulphamethoxazole after renal transplantation.

Authors:  B Hulme; D S Reeves
Journal:  Br Med J       Date:  1971-09-11

7.  Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome.

Authors:  F M Gordin; G L Simon; C B Wofsy; J Mills
Journal:  Ann Intern Med       Date:  1984-04       Impact factor: 25.391

8.  Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole.

Authors:  P P Bradley; G D Warden; J G Maxwell; G Rothstein
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

9.  The effect of trimethoprim/sulfamethoxazole on Friend erythroleukemia cells.

Authors:  S E Steinberg; C L Campbell; P S Rabinovitch; R S Hillman
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191
View more
  4 in total

1.  Improved rat model for studying Pneumocystis carinii pneumonia.

Authors:  M S Bartlett; S F Queener; M A Jay; M M Durkin; J W Smith
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

2.  Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J M Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 3.  Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

4.  Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.

Authors:  P D Walzer; J Foy; P Steele; C K Kim; M White; R S Klein; B A Otter; C Allegra
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.